These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 8073643

  • 1. [Tumor markers in the diagnosis of tumors in the subhepatic area].
    Dufek V, Petrtýl J, Klener P, Chmel J.
    Vnitr Lek; 1994 Jun; 40(6):350-3. PubMed ID: 8073643
    [Abstract] [Full Text] [Related]

  • 2. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
    Scarlett CJ, Saxby AJ, Nielsen A, Bell C, Samra JS, Hugh T, Baxter RC, Smith RC.
    Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
    [Abstract] [Full Text] [Related]

  • 3. [Immunohistochemical analysis for cholangiocarcinoma].
    Nakagoe T, Matsuo T, Kondoh M, Yamaguchi H.
    Nihon Rinsho; 2006 Jan; 64 Suppl 1():370-4. PubMed ID: 16457285
    [No Abstract] [Full Text] [Related]

  • 4. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P.
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [Abstract] [Full Text] [Related]

  • 5. Serum and bile markers for cholangiocarcinoma.
    Nehls O, Gregor M, Klump B.
    Semin Liver Dis; 2004 May; 24(2):139-54. PubMed ID: 15192787
    [Abstract] [Full Text] [Related]

  • 6. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H, Kaya M, Cengiz A.
    Hepatogastroenterology; 2003 May; 50(53):1669-74. PubMed ID: 14571813
    [Abstract] [Full Text] [Related]

  • 7. Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies.
    Brockmann J, Emparan C, Hernandez CA, Sulkowski U, Dietl KH, Menzel J, Wolters H, Glodny B, Senninger N.
    Anticancer Res; 2000 May; 20(6D):4941-7. PubMed ID: 11326643
    [Abstract] [Full Text] [Related]

  • 8. Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract.
    Harmenberg U, Wahren B, Wiechel KL.
    Cancer Res; 1988 Apr 01; 48(7):1985-8. PubMed ID: 3349472
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
    Nishida K, Tasaki N, Miyagawa H, Yoshikawa T, Kondo M.
    Am J Gastroenterol; 1988 Feb 01; 83(2):126-9. PubMed ID: 3422536
    [Abstract] [Full Text] [Related]

  • 11. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.
    Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ.
    Am J Gastroenterol; 2000 Jan 01; 95(1):204-7. PubMed ID: 10638584
    [Abstract] [Full Text] [Related]

  • 12. Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients.
    Torzilli G, Makuuchi M, Ferrero A, Takayama T, Hui AM, Abe H, Inoue K, Nakahara K.
    Hepatogastroenterology; 2002 Jan 01; 49(45):740-5. PubMed ID: 12063982
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Levels of carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) in sera and pancreatic juice in the diagnosis of pancreatic cancer.
    Lin JT, Wang TH, Chen DS, Sung JL.
    Taiwan Yi Xue Hui Za Zhi; 1987 Aug 01; 86(8):823-8. PubMed ID: 3479516
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Tumor markers in the diagnosis of pancreatic carcinoma].
    Lemma F, Bombardieri T, Salibra M, Trovato P, De Pasquale MC, Faraone V, Punturiero R, Di Mauro S.
    Minerva Med; 1989 Jul 01; 80(7):645-9. PubMed ID: 2779818
    [No Abstract] [Full Text] [Related]

  • 17. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.
    Lempinen M, Isoniemi H, Mäkisalo H, Nordin A, Halme L, Arola J, Höckerstedt K, Stenman UH.
    J Hepatol; 2007 Nov 01; 47(5):677-83. PubMed ID: 17640760
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Clinical evaluation of CA 19-9, TPA, IAP and 5'-NPD-V as tumor markers of hepatocellular, bile duct and pancreas carcinoma].
    Takahashi H, Miyazaki H, Deura M, Shimizu Y, Asukata I, Kameda H.
    Gan No Rinsho; 1985 May 01; 31(6 Suppl):623-30. PubMed ID: 2411964
    [Abstract] [Full Text] [Related]

  • 20. The diagnostic significance of carbohydrate antigen CA 19-9 in serum and pancreatic juice in pancreatic carcinoma.
    Chen YF, Mai CR, Tie ZJ, Feng ZT, Zhang J, Lu XH, Lu GJ, Xue YH, Pan GZ.
    Chin Med J (Engl); 1989 May 01; 102(5):333-7. PubMed ID: 2509154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.